BriaCell Therapeutics Corp., a clinical-stage biotechnology company with operations in Philadelphia and Vancouver, said it has obtained an exclusive license for a potential gene therapy from the University of Maryland, Baltimore County.
The new drug candidate, Soluble CD80 (sCD80), is a biologic agent for the treatment of cancer that is designed to restore T cell activation in the immune system.
“Our mission has been to develop safe and effective treatments for cancer patients who do not respond…
